PandemieGrippaleV1, PascalFrancis, Curation, bibRecord, 001904

Effectiveness of H1N1 vaccine for the prevention of pandemic influenza in Scotland, UK: a retrospective observational cohort study

Identifieur interne : 001904 ( PascalFrancis/Curation ); précédent : 001903; suivant : 001905

Effectiveness of H1N1 vaccine for the prevention of pandemic influenza in Scotland, UK: a retrospective observational cohort study

Auteurs : Colin R. Simpson [Royaume-Uni] ; Lewis D. Ritchie [Royaume-Uni] ; Chris Robertson [Royaume-Uni, France] ; Aziz Sheikh [Royaume-Uni] ; Jim Mcmenamin [Royaume-Uni]

Source :

Lancet. Infectious diseases : (print) [ 1473-3099 ] ; 2012.

RBID : Pascal:12-0366222

Descripteurs français

Pascal (Inist)
- Grippe A, Immunoprophylaxie, Prévention, Vaccin, Ecosse, Etude cohorte, Pandémie.
Wicri :
- topic : Vaccin.

English descriptors

KwdEn :
- Cohort study, Immunoprophylaxis, Influenza A, Prevention, Scotland, Vaccine.

Abstract

Background A targeted vaccination programme for pandemic H1N1 2009 influenza was introduced in Scotland, UK, in October, 2009. We sought to assess the effectiveness of this vaccine in a sample of the Scottish population during the 2009-10 pandemic. Methods We assessed the effectiveness of the Scottish pandemic H1N12009 influenza vaccination with a retrospective cohort design. We linked data of patient-level primary care, hospital records, death certification, and virological swabs to construct our cohort. We estimated vaccine effectiveness in a nationally representative sample of the Scottish population by establishing the risk of hospital admission and death (adjusted for potential confounders) resulting from influenza-related morbidity in vaccinated and unvaccinated patients and laboratory-confirmed cases of influenza H1N1 2009 in a subset of patients. Findings Pandemic H1N1 2009 influenza vaccination began in week 43 of 2009 (Oct 21, 2009) and was given to 38 296 (15.5%, 95% CI 15.4-15.6) of 247178 people by the end of the study period (Jan 31, 2010). 208 882 (85%) people were unvaccinated. There were 5207 emergency hospital admissions and 579 deaths in the unvaccinated population and 924 hospital admissions and 71 deaths in the vaccinated population during 23 893 359 person-days of observation. The effectiveness of H1N1 vaccination for prevention of emergency hospital admissions from influenza-related disorders was 19.5% (95% CI 0.8-34.7). The vaccine's effectiveness in preventing laboratory-confirmed influenza was 77.0% (95% CI 2.0-95.0). Interpretation Pandemic H1N12009 influenza vaccination was associated with protection against pandemic influenza and a reduction in hospital admissions from influenza-related disorders in Scotland during the 2009-10 pandemic.

A01	`01`	`1`		`@0 1473-3099`
A03		`1`		`@0 Lancet. Infect. dis. : (print)`
A05				`@2 12`
A06				`@2 9`
A08	`01`	`1`	`ENG`	`@1 Effectiveness of H1N1 vaccine for the prevention of pandemic influenza in Scotland, UK: a retrospective observational cohort study`
A11	`01`	`1`		`@1 SIMPSON (Colin R.)`
A11	`02`	`1`		`@1 RITCHIE (Lewis D.)`
A11	`03`	`1`		`@1 ROBERTSON (Chris)`
A11	`04`	`1`		`@1 SHEIKH (Aziz)`
A11	`05`	`1`		`@1 MCMENAMIN (Jim)`
A14	`01`			`@1 Allergy and Respiratory Research Group, Centre for Population Health Sciences, The University of Edinburgh @2 Edinburgh @3 GBR @Z 1 aut. @Z 4 aut.`
A14	`02`			`@1 Centre of Academic Primary Care, University of Aberdeen @2 Aberdeen @3 GBR @Z 2 aut.`
A14	`03`			`@1 Department of Mathematics and Statistics, University of Strathclyde @2 Glasgow @3 GBR @Z 3 aut.`
A14	`04`			`@1 Health Protection Scotland @2 Glasgow @3 GBR @Z 3 aut. @Z 5 aut.`
A14	`05`			`@1 International Prevention Research Institute @2 Lyon @3 FRA @Z 3 aut.`
A20				`@1 696-702`
A21				`@1 2012`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 27478 @5 354000504472350160`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 38 ref.`
A47	`01`	`1`		`@0 12-0366222`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Lancet. Infectious diseases : (print)`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Background A targeted vaccination programme for pandemic H1N1 2009 influenza was introduced in Scotland, UK, in October, 2009. We sought to assess the effectiveness of this vaccine in a sample of the Scottish population during the 2009-10 pandemic. Methods We assessed the effectiveness of the Scottish pandemic H1N12009 influenza vaccination with a retrospective cohort design. We linked data of patient-level primary care, hospital records, death certification, and virological swabs to construct our cohort. We estimated vaccine effectiveness in a nationally representative sample of the Scottish population by establishing the risk of hospital admission and death (adjusted for potential confounders) resulting from influenza-related morbidity in vaccinated and unvaccinated patients and laboratory-confirmed cases of influenza H1N1 2009 in a subset of patients. Findings Pandemic H1N1 2009 influenza vaccination began in week 43 of 2009 (Oct 21, 2009) and was given to 38 296 (15.5%, 95% CI 15.4-15.6) of 247178 people by the end of the study period (Jan 31, 2010). 208 882 (85%) people were unvaccinated. There were 5207 emergency hospital admissions and 579 deaths in the unvaccinated population and 924 hospital admissions and 71 deaths in the vaccinated population during 23 893 359 person-days of observation. The effectiveness of H1N1 vaccination for prevention of emergency hospital admissions from influenza-related disorders was 19.5% (95% CI 0.8-34.7). The vaccine's effectiveness in preventing laboratory-confirmed influenza was 77.0% (95% CI 2.0-95.0). Interpretation Pandemic H1N12009 influenza vaccination was associated with protection against pandemic influenza and a reduction in hospital admissions from influenza-related disorders in Scotland during the 2009-10 pandemic.
C02	`01`	`X`		`@0 002B05C02C`
C03	`01`	`X`	`FRE`	`@0 Grippe A @5 01`
C03	`01`	`X`	`ENG`	`@0 Influenza A @5 01`
C03	`01`	`X`	`SPA`	`@0 Gripe A @5 01`
C03	`02`	`X`	`FRE`	`@0 Immunoprophylaxie @5 04`
C03	`02`	`X`	`ENG`	`@0 Immunoprophylaxis @5 04`
C03	`02`	`X`	`SPA`	`@0 Inmunoprofilaxia @5 04`
C03	`03`	`X`	`FRE`	`@0 Prévention @5 07`
C03	`03`	`X`	`ENG`	`@0 Prevention @5 07`
C03	`03`	`X`	`SPA`	`@0 Prevención @5 07`
C03	`04`	`X`	`FRE`	`@0 Vaccin @5 08`
C03	`04`	`X`	`ENG`	`@0 Vaccine @5 08`
C03	`04`	`X`	`SPA`	`@0 Vacuna @5 08`
C03	`05`	`X`	`FRE`	`@0 Ecosse @2 NG @5 09`
C03	`05`	`X`	`ENG`	`@0 Scotland @2 NG @5 09`
C03	`05`	`X`	`SPA`	`@0 Escocia @2 NG @5 09`
C03	`06`	`X`	`FRE`	`@0 Etude cohorte @5 14`
C03	`06`	`X`	`ENG`	`@0 Cohort study @5 14`
C03	`06`	`X`	`SPA`	`@0 Estudio cohorte @5 14`
C03	`07`	`X`	`FRE`	`@0 Pandémie @4 INC @5 86`
C07	`01`	`X`	`FRE`	`@0 Virose`
C07	`01`	`X`	`ENG`	`@0 Viral disease`
C07	`01`	`X`	`SPA`	`@0 Virosis`
C07	`02`	`X`	`FRE`	`@0 Infection`
C07	`02`	`X`	`ENG`	`@0 Infection`
C07	`02`	`X`	`SPA`	`@0 Infección`
C07	`03`	`X`	`FRE`	`@0 Grande Bretagne @2 NG`
C07	`03`	`X`	`ENG`	`@0 Great Britain @2 NG`
C07	`03`	`X`	`SPA`	`@0 Gran Bretaña @2 NG`
C07	`04`	`X`	`FRE`	`@0 Royaume-Uni @2 NG`
C07	`04`	`X`	`ENG`	`@0 United Kingdom @2 NG`
C07	`04`	`X`	`SPA`	`@0 Reino Unido @2 NG`
C07	`05`	`X`	`FRE`	`@0 Europe @2 NG`
C07	`05`	`X`	`ENG`	`@0 Europe @2 NG`
C07	`05`	`X`	`SPA`	`@0 Europa @2 NG`
N21				`@1 282`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000534

Links to Exploration step

Pascal:12-0366222

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effectiveness of H1N1 vaccine for the prevention of pandemic influenza in Scotland, UK: a retrospective observational cohort study</title>
<author><name sortKey="Simpson, Colin R" sort="Simpson, Colin R" uniqKey="Simpson C" first="Colin R." last="Simpson">Colin R. Simpson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Allergy and Respiratory Research Group, Centre for Population Health Sciences, The University of Edinburgh</s1>
<s2>Edinburgh</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Ritchie, Lewis D" sort="Ritchie, Lewis D" uniqKey="Ritchie L" first="Lewis D." last="Ritchie">Lewis D. Ritchie</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre of Academic Primary Care, University of Aberdeen</s1>
<s2>Aberdeen</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Robertson, Chris" sort="Robertson, Chris" uniqKey="Robertson C" first="Chris" last="Robertson">Chris Robertson</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Mathematics and Statistics, University of Strathclyde</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Health Protection Scotland</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>International Prevention Research Institute</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Sheikh, Aziz" sort="Sheikh, Aziz" uniqKey="Sheikh A" first="Aziz" last="Sheikh">Aziz Sheikh</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Allergy and Respiratory Research Group, Centre for Population Health Sciences, The University of Edinburgh</s1>
<s2>Edinburgh</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Mcmenamin, Jim" sort="Mcmenamin, Jim" uniqKey="Mcmenamin J" first="Jim" last="Mcmenamin">Jim Mcmenamin</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Health Protection Scotland</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0366222</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0366222 INIST</idno>
<idno type="RBID">Pascal:12-0366222</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000534</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001904</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effectiveness of H1N1 vaccine for the prevention of pandemic influenza in Scotland, UK: a retrospective observational cohort study</title>
<author><name sortKey="Simpson, Colin R" sort="Simpson, Colin R" uniqKey="Simpson C" first="Colin R." last="Simpson">Colin R. Simpson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Allergy and Respiratory Research Group, Centre for Population Health Sciences, The University of Edinburgh</s1>
<s2>Edinburgh</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Ritchie, Lewis D" sort="Ritchie, Lewis D" uniqKey="Ritchie L" first="Lewis D." last="Ritchie">Lewis D. Ritchie</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre of Academic Primary Care, University of Aberdeen</s1>
<s2>Aberdeen</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Robertson, Chris" sort="Robertson, Chris" uniqKey="Robertson C" first="Chris" last="Robertson">Chris Robertson</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Mathematics and Statistics, University of Strathclyde</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Health Protection Scotland</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>International Prevention Research Institute</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Sheikh, Aziz" sort="Sheikh, Aziz" uniqKey="Sheikh A" first="Aziz" last="Sheikh">Aziz Sheikh</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Allergy and Respiratory Research Group, Centre for Population Health Sciences, The University of Edinburgh</s1>
<s2>Edinburgh</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Mcmenamin, Jim" sort="Mcmenamin, Jim" uniqKey="Mcmenamin J" first="Jim" last="Mcmenamin">Jim Mcmenamin</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Health Protection Scotland</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Lancet. Infectious diseases : (print)</title>
<title level="j" type="abbreviated">Lancet. Infect.  dis. : (print)</title>
<idno type="ISSN">1473-3099</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Lancet. Infectious diseases : (print)</title>
<title level="j" type="abbreviated">Lancet. Infect.  dis. : (print)</title>
<idno type="ISSN">1473-3099</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cohort study</term>
<term>Immunoprophylaxis</term>
<term>Influenza A</term>
<term>Prevention</term>
<term>Scotland</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Grippe A</term>
<term>Immunoprophylaxie</term>
<term>Prévention</term>
<term>Vaccin</term>
<term>Ecosse</term>
<term>Etude cohorte</term>
<term>Pandémie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background A targeted vaccination programme for pandemic H1N1 2009 influenza was introduced in Scotland, UK, in October, 2009. We sought to assess the effectiveness of this vaccine in a sample of the Scottish population during the 2009-10 pandemic. Methods We assessed the effectiveness of the Scottish pandemic H1N12009 influenza vaccination with a retrospective cohort design. We linked data of patient-level primary care, hospital records, death certification, and virological swabs to construct our cohort. We estimated vaccine effectiveness in a nationally representative sample of the Scottish population by establishing the risk of hospital admission and death (adjusted for potential confounders) resulting from influenza-related morbidity in vaccinated and unvaccinated patients and laboratory-confirmed cases of influenza H1N1 2009 in a subset of patients. Findings Pandemic H1N1 2009 influenza vaccination began in week 43 of 2009 (Oct 21, 2009) and was given to 38 296 (15.5%, 95% CI 15.4-15.6) of 247178 people by the end of the study period (Jan 31, 2010). 208 882 (85%) people were unvaccinated. There were 5207 emergency hospital admissions and 579 deaths in the unvaccinated population and 924 hospital admissions and 71 deaths in the vaccinated population during 23 893 359 person-days of observation. The effectiveness of H1N1 vaccination for prevention of emergency hospital admissions from influenza-related disorders was 19.5% (95% CI 0.8-34.7). The vaccine's effectiveness in preventing laboratory-confirmed influenza was 77.0% (95% CI 2.0-95.0). Interpretation Pandemic H1N12009 influenza vaccination was associated with protection against pandemic influenza and a reduction in hospital admissions from influenza-related disorders in Scotland during the 2009-10 pandemic.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1473-3099</s0>
</fA01>
<fA03 i2="1"><s0>Lancet. Infect.  dis. : (print)</s0>
</fA03>
<fA05><s2>12</s2>
</fA05>
<fA06><s2>9</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Effectiveness of H1N1 vaccine for the prevention of pandemic influenza in Scotland, UK: a retrospective observational cohort study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SIMPSON (Colin R.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>RITCHIE (Lewis D.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>ROBERTSON (Chris)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SHEIKH (Aziz)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MCMENAMIN (Jim)</s1>
</fA11>
<fA14 i1="01"><s1>Allergy and Respiratory Research Group, Centre for Population Health Sciences, The University of Edinburgh</s1>
<s2>Edinburgh</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Centre of Academic Primary Care, University of Aberdeen</s1>
<s2>Aberdeen</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Mathematics and Statistics, University of Strathclyde</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Health Protection Scotland</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>International Prevention Research Institute</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>696-702</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>27478</s2>
<s5>354000504472350160</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>38 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0366222</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Lancet. Infectious diseases : (print)</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background A targeted vaccination programme for pandemic H1N1 2009 influenza was introduced in Scotland, UK, in October, 2009. We sought to assess the effectiveness of this vaccine in a sample of the Scottish population during the 2009-10 pandemic. Methods We assessed the effectiveness of the Scottish pandemic H1N12009 influenza vaccination with a retrospective cohort design. We linked data of patient-level primary care, hospital records, death certification, and virological swabs to construct our cohort. We estimated vaccine effectiveness in a nationally representative sample of the Scottish population by establishing the risk of hospital admission and death (adjusted for potential confounders) resulting from influenza-related morbidity in vaccinated and unvaccinated patients and laboratory-confirmed cases of influenza H1N1 2009 in a subset of patients. Findings Pandemic H1N1 2009 influenza vaccination began in week 43 of 2009 (Oct 21, 2009) and was given to 38 296 (15.5%, 95% CI 15.4-15.6) of 247178 people by the end of the study period (Jan 31, 2010). 208 882 (85%) people were unvaccinated. There were 5207 emergency hospital admissions and 579 deaths in the unvaccinated population and 924 hospital admissions and 71 deaths in the vaccinated population during 23 893 359 person-days of observation. The effectiveness of H1N1 vaccination for prevention of emergency hospital admissions from influenza-related disorders was 19.5% (95% CI 0.8-34.7). The vaccine's effectiveness in preventing laboratory-confirmed influenza was 77.0% (95% CI 2.0-95.0). Interpretation Pandemic H1N12009 influenza vaccination was associated with protection against pandemic influenza and a reduction in hospital admissions from influenza-related disorders in Scotland during the 2009-10 pandemic.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B05C02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Grippe A</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Influenza A</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Gripe A</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Immunoprophylaxie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Immunoprophylaxis</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Inmunoprofilaxia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Prévention</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Prevention</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Prevención</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Ecosse</s0>
<s2>NG</s2>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Scotland</s0>
<s2>NG</s2>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Escocia</s0>
<s2>NG</s2>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Etude cohorte</s0>
<s5>14</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Cohort study</s0>
<s5>14</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Estudio cohorte</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Pandémie</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Grande Bretagne</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Great Britain</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Gran Bretaña</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Royaume-Uni</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>United Kingdom</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Reino Unido</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Europe</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Europe</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Europa</s0>
<s2>NG</s2>
</fC07>
<fN21><s1>282</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001904 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001904 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:12-0366222
   |texte=   Effectiveness of H1N1 vaccine for the prevention of pandemic influenza in Scotland, UK: a retrospective observational cohort study
}}

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Effectiveness of H1N1 vaccine for the prevention of pandemic influenza in Scotland, UK: a retrospective observational cohort study

Effectiveness of H1N1 vaccine for the prevention of pandemic influenza in Scotland, UK: a retrospective observational cohort study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri